This is believed to be the first evidence of a doomed gene “ infection-fighting human IRGM “ making a comeback in the human/great ape lineage. The study, led by Evan Eichler's genome science laboratory at the University of Washington and the Howard Hughes Medical Institute, is published March 6 in the open-access journal PLoS Genetics .
The truncated IRGM gene is one of only two genes of its type remaining in humans. The genes are Immune-Related GTPases, a kind of gene that helps mammals resist germs like tuberculosis and salmonella that try to invade cells. Unlike humans, most other mammals have several genes of this type. Mice, for example, have 21 Immune-Related GTPases. Medical interest in this gene ignited recently, when scientists associated specific IRGM mutations with the risk of Crohn's disease, an inflammatory digestive disorder.
In this latest study, the researchers reconstructed the evolutionary history of the IRGM locus within primates. They found that most of the gene cluster was eliminated by going from multiple copies to a sole copy early in primate evolution, approximately 50 million years ago. Comparisons of Old World and New World monkey species suggest that the remaining copy died in their common ancestor.
The gene remnant continued to be inherited through millions of years of evolution. Then, in the common ancestor of humans and great apes, something unexpected happened. Once again the gene could be read to produce proteins. Evidence suggests that this change coincided with a retrovirus insertion in the ancestral genome.
"The IRGM gene was dead and later resurrected through a complex series of structural events," Eichler said. "These findings tell us that we shouldn't count a gene out until it is completely deleted."
The structural analysis, he added, also suggests a remarkable functional plasticity in genes that experience a variety of evolutionary pressures over time. Such malleability may be especially useful for genes that help in the fight against new or newly resistant infectious agents.
plos/
This has been confirmed by Christine Van Broeckhoven's team, who have shown that a shortage of this growth factor leads to the dying off of brain cells in the frontal lobe and in this way causes FTD. New results indicate that progranulin also plays a role in the death of brain cells in other diseases of the brain, such as Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS).
Predictive test
On the basis of their research, Kristel Sleegers, a scientist in Van Broeckhoven's team, has developed a test for measuring the quantity of progranulin in the blood in a simple way. This test enables one to determine whether someone has an increased risk of FTD due to a shortage of progranulin long before symptoms appear. The blood test can be used on a large scale and is much more simple and user-friendly than the current genetic tests. This finding also offers prospects for the early detection of FTD caused by a shortage of progranulin.
However, it is still too early for a medicine to combat FTD. Further scientific research is needed to determine how a shortage of progranulin can be restored to normal.
vib.be/VIB/EN/